Prab: CSV import

2025-02-20T01:17:11Z

CSV import

← Older revision		Revision as of 01:17, 20 February 2025
Line 34:		Line 34:

	{{Pharmacology-stub}}		{{Pharmacology-stub}}
			== Halofuginone ==
			<gallery>
			File:Halofuginone.png\|Halofuginone
			File:Halofuginone molecule ball.png\|Halofuginone molecule ball
			</gallery>

Prab: CSV import

2024-03-22T12:54:20Z

CSV import

New page

'''Halofuginone''' is a [[quinazolinone]] alkaloid derived from the plant ''[[Dichroa febrifuga]]'' or blue evergreen hydrangea. It has been investigated for various medical and agricultural applications due to its anti-fibrotic, anti-inflammatory, and antiparasitic properties. Halofuginone inhibits the development of [[T helper 17 cells]] (Th17 cells), which are implicated in autoimmune diseases, by blocking the [[amino acid]] starvation response and the synthesis of [[proline]], an amino acid critical for the synthesis of [[collagen]].

==History==
Halofuginone's origins trace back to traditional Chinese medicine, where ''Dichroa febrifuga'' was used to treat malaria and fever. Its antimalarial properties were attributed to febrifugine, a compound related to halofuginone. In the 20th century, halofuginone was synthesized and explored for its potential in veterinary medicine, particularly in the prevention of [[coccidiosis]] in poultry.

==Mechanism of Action==
Halofuginone exerts its effects through several mechanisms. Primarily, it inhibits the [[TGF-β]]/[[Smad3]] signaling pathway, which is crucial for the activation of fibroblasts and the production of extracellular matrix components like collagen. By doing so, halofuginone can reduce fibrosis in various organs, including the liver, lung, and kidney. Additionally, halofuginone inhibits the differentiation of Th17 cells by activating the amino acid starvation response (AAR) pathway, leading to the suppression of pro-inflammatory cytokines.

==Clinical Applications==
###Anti-fibrotic Therapy###
Halofuginone has shown promise in treating fibrotic diseases, such as [[scleroderma]], [[pulmonary fibrosis]], and [[liver fibrosis]]. Its ability to inhibit collagen synthesis and fibroblast activation makes it a potential therapeutic agent against fibrosis.

###Autoimmune Diseases###
Due to its effect on Th17 cells, halofuginone is also being studied for its potential in treating autoimmune diseases, including [[multiple sclerosis]], [[rheumatoid arthritis]], and [[inflammatory bowel disease]].

###Antiparasitic Use###
In veterinary medicine, halofuginone is used to prevent and treat coccidiosis in poultry, a disease caused by parasitic protozoa of the genus ''[[Eimeria]]''.

==Adverse Effects==
While halofuginone is beneficial in various therapeutic applications, it can cause side effects such as reduced feed intake and growth retardation in animals. The safety and efficacy of halofuginone in humans are still under investigation, with potential adverse effects being a concern for long-term use.

==Research Directions==
Research on halofuginone is ongoing, with studies exploring its mechanism of action, potential therapeutic applications, and safety profile. Its role in treating fibrotic diseases and autoimmune conditions remains a promising area of investigation.

==See Also==
* [[Fibrosis]]
* [[Autoimmune disease]]
* [[T helper cell]]
* [[Collagen]]

[[Category:Alkaloids]]
[[Category:Anti-fibrotic agents]]
[[Category:Antiparasitic agents]]

{{Pharmacology-stub}}

Halofuginone - Revision history

Prab: CSV import

Prab: CSV import